Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
DYN
DYN
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
DYN News
U.S. Stocks Rise as NIO Reports Strong Earnings
6h ago
Benzinga
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
1d ago
Benzinga
Dyne Therapeutics Announces Major Clinical Updates on DMD and DM1 Trials
1d ago
NASDAQ.COM
Dyne Therapeutics Initiates Phase 3 HARMONIA Trial for DM1
1d ago
Newsfilter
FDA Rejects Multiple Experimental Drug Applications, Raising Investor Concerns
4d ago
CNBC
FDA Drug Approval Uncertainty Intensifies
4d ago
Newsfilter
Palo Alto Investors Increases Stake in Dyne Therapeutics
Mar 02 2026
Fool
Dyne Therapeutics Q4 Earnings Beat Expectations
Mar 02 2026
seekingalpha
Dyne Therapeutics Advances DMD Treatment Progress
Mar 02 2026
Newsfilter
Sarepta Therapeutics Reports Earnings Miss and Management Transition
Feb 26 2026
Benzinga
Dyne Therapeutics to Participate in Upcoming Investor Conferences
Feb 25 2026
Newsfilter
Dyne Announces Positive Results from DELIVER Trial for DMD at MDA Conference
Feb 22 2026
Newsfilter
Dyne Therapeutics Receives Orphan Drug Designation for z-basivarsen, ACHIEVE Trial Shows Sustained Improvement
Jan 20 2026
Globenewswire
Stocks to Consider Buying in 2026: Insights from Our Roundtable Experts, Including DoorDash and LVMH
Jan 16 2026
Barron's
Dyne Therapeutics Closes $402.5 Million Upsized Public Offering
Dec 11 2025
Globenewswire
Dyne Therapeutics Closes $402.5 Million Upsized Public Offering
Dec 11 2025
Newsfilter
Show More News
